Download MendeleyDevelopment of conformation-selective antibodies targeting human SLC15A4.
Zhu, Y., Zhang, X., Zhang, Q., Sun, P., Liu, K., Nie, X., Ma, J., Zhang, L., Gao, Y., Wang, Y., Liu, S., Gao, A., Zhang, L., Gao, P.(2025) Nat Commun 16: 7324-7324
- PubMed: 40781080
- DOI: https://doi.org/10.1038/s41467-025-62759-x
- Primary Citation of Related Structures:
9IRB, 9IRC - PubMed Abstract:
SLC15A4, an endolysosomal solute carrier family transporter, plays a critical role in TLR7/8/9-induced immune responses through assembling a complex with the downstream adaptor TASL in a conformation-dependent manner. Despite its close functional association and promising therapeutic potential in infections, tumors, and autoimmune diseases, the development of conformation-specific antibodies for human SLC15A4 (hSLC15A4) remains challenging. Here, using a systematic screening and validation approach, we identify a pair of conformation-selective antibodies, clones 107 and 235, targeting the endolysosomal lumen surface of hSLC15A4 with opposite conformation-regulatory activities. Specifically, clone 107 selectively binds to hSLC15A4 in a TASL binding-incompetent luminal-open state; whereas clone 235 stabilizes hSLC15A4 in a TASL binding-competent cytoplasmic-open state. Our research identifies antibodies that recognize distinct conformations of hSLC15A4, potentially enabling modulation of the TLR7/8/9 pathway and contributing to the development of targeted therapies and research tools selectively targeting hSLC15A4.
- Key Laboratory of Molecular Medicine and Biotherapy, Aerospace Center Hospital, School of Life Science, Beijing Institute of Technology, Beijing, China.
Organizational Affiliation:
